Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 18

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 18
---
5 (Consolidated)

(ii) Consolidated Cash Flows

|                                                                   |     | Billion JPY |        |     |           |        |     |        |        |
|                                                                   |     | FY2024 Q1   |        |     | FY2025 Q1 |        |     | Change |        |
| Net cash from operating activities                                |     |             |  170.3 |     |           |  215.4 |     |        |   45.1 |
| Net cash used in investing activities                             |     |             | -156.7 |     |           |  -33.2 |     |        |  123.5 |
| Net cash from (used in) financing activities                      |     |             |  316.4 |     |           | -214.9 |     |        | -531.3 |
| Net increase (decrease) in cash and cash equivalents              |     |             |  330.0 |     |           |  -32.7 |     |        | -362.7 |
| Cash and cash equivalents at the beginning of the year            |     |             |  457.8 |     |           |  385.1 |     |        |  -72.7 |
| Effects of exchange rate changes on cash and cash equivalents     |     |             |   17.2 |     |           |   -2.4 |     |        |  -19.7 |
| Cash and cash equivalents reclassified to assets held for sale    |     |             |   -0.7 |     |           |      — |     |        |    0.7 |
| Cash and cash equivalents at the end of the period                
 (Condensed interim consolidated statements of financial position) |     |             |  804.3 |     |           |  350.0 |     |        | -454.3 |

#### Net Cash from Operating Activities
Net Cash from Operating Activities was JPY 215.4 billion ( JPY +45.1 billion ). The increase was mainly due to favorable impacts from Changes in Assets and Liabilities primarily driven by changes in Trade and Other Receivables, Provisions and Other Financial Liabilities. The increase was partially offset by unfavorable impacts resulting from Net Profit for the Period adjusted for non-cash items and other adjustments.

#### Net Cash used in Investing Activities
Net Cash used in Investing Activities was JPY